-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$94.5014.59% Upside
Recent Analyst Forecasts and Stock Ratings
Intra-Cellular Therapies, Inc. Frequently Asked Questions
-
What analysts cover Intra-Cellular Therapies, Inc.?
Intra-Cellular Therapies, Inc. has been rated by research analysts at Goldman Sachs, Piper Sandler, RBC Capital, Needham, UBS, Mizuho Securities in the past 90 days.